& This is the first dose7response meta7analysis on the relationship between calcium intake and colorectal adenomas. By showing a continued reduction in risk of adenomas, particularly high7 risk adenomas ( ≥ 1 cm in diameter, (tubulo)villous histology, dysplasia, or multiplicity), beyond 1,000 mg/day of total calcium intake, our results suggest that calcium may have chemopreventive potential against colorectal neoplasia, irrespective of baseline total calcium intake over a wide range.
Evidence from randomized controlled trials suggests that calcium may protect against recurrence of colorectal adenomas, which could lead to the subsequent prevention of cancer. Yet, because the trials used only a large single dose and were of small sizes, knowledge of the dose7response relationship and influence on high7risk adenomas is limited. To address these issues, we conducted linear and non7linear dose7response meta7analyses primarily based on prospective observational studies published up to July 2014 identified from PubMed and Embase. Summary relative risks (RRs) and 95% confidence intervals (CIs) were calculated for total and supplemental calcium intake, respectively, using a random7effects model. For total calcium intake, summary RR for each 300mg/day increase was 0.95(95% CI=0.9270.98; I 2 =45%; 8 studies with 11,005 cases; range of intake=33372,229 mg/day). Evidence of non7linearity was indicated: approximately, compared to 550 mg/day of total calcium intake, the summary RR was 0.92(95% CI=0.8970.94) at 1000 mg/day and 0.87(95% CI=0.8470.90) at 1450 mg/day (P non7 linearity <0.01). Associations were stronger for high7risk adenomas (≥1 cm in diameter, (tubulo)villous histology, dysplasia, or multiplicity): approximately, compared to 550 mg/day of total calcium intake, the summary RR was 0.77(95% CI=0.7470.81) at 1000 mg/day and reduced to 0.69(95% CI=0.6670.73) at 1450 mg/da (P non7linearity <0.01). For supplemental calcium intake, summary RR of total adenoma risk for each 300mg/day increase was 0.96(95% CI=0.9370.99; I 2 =0%; 3 studies with 4,548 cases; range of supplementation=071,366 mg/day). In conclusion, calcium intake may continue to decrease the risk of adenomas, particularly high7risk adenomas, over a wide range of calcium intake.
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For the design, analysis, and reporting of this study, the Meta7analysis Of Observational Studies in Epidemiology (MOOSE) checklist 10 was followed for meta7analysis of prospective observational studies. Two authors (DL and NK) participated in literature search, study selection, and data extraction independently. Inconsistency between researchers was resolved through discussion.
' ! PubMed and Embase databases were searched for studies published up to July 2014. Detailed search terms are provided (Supplementary Table 1 ). The language was limited to English and no other restrictions were imposed. Abstracts and unpublished results were not included. The reference lists of selected reviews and meta7analyses, and all the articles included in our analysis were also reviewed for additional studies.
To be included, studies had to be an observational study (e.g. cross7sectional, case7 control, or cohort study) investigating the relationship between calcium intake and colorectal adenomas. For dose7response meta7analysis, studies had to provide the following information: a quantitative measure of calcium intake for at least 3 categories with the estimates of RRs (odds ratio, rate ratio, or hazard ratio), 95% confidence interval (CI), category7specific or total number of cases, and category7specific or total number of either noncases or person7years. When there were several publications from the same cohort, the publication with the largest number of cases was selected. Authors of two cohort studies 11, 12 were contacted for additional data and one 11 of the two studies could be incorporated in dose7response meta7analysis. The procedure of study selection, including reasons for exclusion, is summarized in Figure 1 .
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From each study, the following information was extracted: the most fully adjusted RR and corresponding 95% CI in each category of calcium intake, category7specific range of calcium intake, category7specific or total number of cases, category7specific or total number of person7years (for rate ratio or hazard ratio) or noncases (for odds ratio), types of calcium intake (total=dietary+supplemental, dietary, supplemental), mean or median calcium intake of source population at study entry, subtypes of adenomas by anatomic location and propensity to progress to colorectal cancer (high risk adenoma characterized by large size of ≥ 1 cm in diameters, (tubulo)villous histology, dysplasia, or multiplicity vs. small adenomas), first author's name, publication year, study design, study name, country of the study population, sex, age at enrollment, sample size, number of cases, study period, dietary assessment method (type, whether it had been validated), adjustment variables, temporality (i.e. prospective: diet was assessed prior to participants' knowledge of adenoma status; retrospective: diet was assessed prior to participants' knowledge of adenoma status).
Across cross7sectional, case7control, or cohort studies, cohort studies are generally least prone to biases. However, the asymptomatic nature of adenomas reduced methodological distinctions across the study designs in the investigation of calcium intake and adenoma risk. For instances, as the true case and control status can be determined only at time of endoscopy, 5 most studies defined the source population as subjects who underwent an endoscopy. Furthermore, as the timing of endoscopy was not necessarily guided by symptoms, time from study baseline to adenoma detection is rather arbitrary. Thus, like the other study designs, most cohort studies used logistic regression only accounting for whether or not an event happens rather than Cox regression incorporating both whether or not and when an event happens. For these reasons, one of the most important methodological distinctions narrowed down to temporal relationship between the assessment of calcium intake and participants' knowledge about their adenoma status. As studies that prospectively assessed calcium intake are less prone to recall bias than those that retrospectively assessed, prospective studies constituted our primary analysis.
Furthermore, out of the three possible types of calcium intake (total, dietary, supplemental), total calcium intake is the exposure measure that is most relevant to exploring a dose7response relationship between calcium intake and adenoma risk. Thus, our primary meta7 analysis included prospective studies that investigated total calcium intake. To enhance the comparability of our results with RCTs that tested the effect of supplemental calcium, a dose7 response meta7analysis was also conducted based on prospective studies that investigated supplemental calcium.
Linear and non7linear dose7response meta7analyses were conducted. For linear dose7 response meta7analysis assuming a linear relationship between calcium intake and adenoma risk, the method described by Greenland and Longnecker 13 was used to calculate study7specific RRs (linear slopes) and 95% CIs from the correlated RRs and 95% CIs extracted across categories of calcium intake. In estimating study7specific linear trends, several approximations were made: the midpoint of calcium intake in each category was assigned to the corresponding RR; the width of the open7ended extreme categories was assumed to be the same as that of the adjacent interval; when the distributions of person7years or non7cases were not provided but analyzed based on quantiles, they were equally divided across the quantiles; for studies 14, 15 that showed results separately for distal and rectal adenomas or for men and women, category7specific RRs and variances were combined using a fixed effects model based on inverse variance weight to obtain combined estimates for colorectal adenomas or for both sexes, before estimating the study7specific RR and 95% CI; for one study 16 that used the sixth lowest category of calcium intake as the reference, the method by Hamling et al 17 was used to estimate new RRs and 95% CIs setting the lowest category as the new reference. Then, the estimated study7specific RRs and variances were pooled using a random effects model to calculate the summary RR and 95% CI. Forest plots of the linear dose7response meta7analysis were presented for RRs for each 300mg/day increment of calcium intake (the unit equivalent to calcium content in one serving (250 mL) of milk).
To examine potential non7linear relationship between calcium intake and adenoma risk, non7linear dose7response meta7analysis was performed based on the restricted cubic spline approach. 18, 19 Of note, this approach requires that studies have more than three categories of calcium intake. For each study, cubic splines were modeled with three knots fixed at percentiles (10%, 50%, and 90%) of the whole distribution of calcium intake, accounting for correlation across category7specific RRs and 95% CIs within each study. 18 The reference was set to 550 mg/day, the lowest value of the reported calcium intakes that were concentrated in lower extremes. Then, the derived curves were combined using multivariate random7effects meta7 analysis. 20 The p7value for nonlinearity was obtained from the test of the null hypothesis that the regression coefficient of the second spline transformation was equal to zero. Heterogeneity in the relationship between calcium intake and adenomas across studies was assessed by I 2 and Q test. 21 Subgroup analyses and meta7regression were conducted by 6 selected variables related to etiologic heterogeneity and potential effect modifiers to identify sources of heterogeneity; by variables concerning methodological characteristics to assess study quality. Potential for small study effects, 22, 23 such as publication bias, was assessed visually using funnel plots and statistically using Egger's test. 24 Upon the detection of statistically significant evidence of small study effects, contour7enhanced funnel plot was plotted that distinguishes areas of the statistical significance and non7significance of the funnel plot using contour. 25, 26 By presenting each study in the context of statistical significance, this plot helps determine if the cause of asymmetry is attributable to publication bias based on statistical significance. 25 To explore robustness of the results, diverse sensitivity analyses including the influence analysis and highest vs. lowest meta7analysis that pooled RRs for the extreme categories of calcium intake using a random effects model were performed. For statistical significance, two7sided α was set at P=0.05. All statistical analyses were conducted using STATA 12 (StataCorp, College Station, TX).
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A total of 14 studies 11, 14716, 27736 were eligible for the inclusion in dose7response meta7 analysis of total calcium intake and adenoma risk (Supplementary Table 2) . Across the studies, types of adenomas investigated varied. The study by Lieberman et al. 27 specifically investigated advanced adenomas and the other 13 studies primarily examined total adenomas with some studies 11, 16, 27, 29, 34, 35 further conducting subgroup analysis by adenoma subtypes. Two studies 35, 36 exclusively investigated recurrent adenomas and the other 12 studies examined occurrent adenomas. While accumulating evidence suggests that calcium may be more protective against advanced adenomas, 9, 11, 16, 29, 35 there is no sufficient a priori evidence to suspect that the effect of calcium may differ by recurrent vs. occurrent adenomas. Thus, dose7response meta7analysis of total calcium intake and adenoma risk was based on 13 studies 11, 14716, 28736 excluding the study by Lieberman et al., 27 which was included only in the subgroup analysis for high7risk adenomas. Out of the 13 studies, 11, 14716, 28736 eight studies 11, 14, 16, 29, 31, 34736 qualified for prospective studies, including a total of 11,005 cases with category7specific midpoints of total calcium intake ranging from 333 to 2,229 mg/day; the remaining five studies were classified as retrospective studies (2,401 cases, range=28571405 mg/day).
In the linear dose7response meta7analysis of eight prospective studies, 11, 14, 16, 29, 31, 34736 each 300 mg/day increase in total calcium intake was associated with an approximately 5% decreased risk of adenomas (RR=0.95, 95% CI=0.9270.98), with moderate heterogeneity (I 2 =45%, P heterogeneity =0.08) ( Figure 2A ). The linear association was stronger among retrospective studies (RR=0.91, 95% CI=0.8271.01), but it was not statistically significant and had a greater degree of heterogeneity (I 2 =58%, P heterogeneity =0.05) ( Figure 2B ). There was no evidence of heterogeneity by prospective vs. retrospective assessment of calcium intake (P heterogeneity =0.67).
In sensitivity analyses such as excluding one study at a time and including one additional prospective studies 37 that reported dietary calcium intake instead of total calcium intake, the results did not change materially (data not shown).
In the non7linear dose7response meta7analysis, after excluding one study 31 that analyzed calcium intake in three categories only, seven prospective studies 11, 14, 16, 29, 34736 were included (10,828 cases, range=33372,229 mg/day). Moderate non7linearity was apparent, with adenoma risk decreasing more steeply in the lower range of total calcium intake than in the higher range (P non7linearity <0.01) ( Figure 3A ). Approximately, compared to 550 mg/day of total calcium intake, the summary RR was 0.92 (95% CI=0.8970.94) at 1000 mg/day and further reduced to 0.87 (95% CI=0.8470.90) at 1450 mg/day.
Although the number of prospective studies was limited, small study effects, such as publication bias, were indicated by asymmetry in the funnel plot and Egger's test (P<0.01)( Figure 4 ). Several sensitivity analyses were performed. First, when an equivalent analysis was run using a fixed effects model, which gives less weight to small studies compared to a random effects model, the association was attenuated but still statistically significant (RR=0.96, 95% CI=0.9570.98, I
2 =45%, P heterogeneity =0.08). Second, contour7enhanced funnel plot indicated that potential missing studies were likely to be located in both statistically significant and non7significant areas, reducing the possibility of publication bias based on statistical significance to explain the observed asymmetry ( Figure 4 ). Third, when highest vs. lowest meta7 analysis was performed including two additional prospective studies 12, 37 that were not eligible for dose7response analysis due to insufficient information, a significant inverse association 8 persisted (RR=0.84, 95% CI=0.7870.92) with no evidence of heterogeneity (I 2 =0%, P heterogeneity =0.47) and no evidence of small study effects(P Egger =0.35) (Supplementary Figure 1) .
To explore if the inverse association with calcium was stronger against high7risk adenomas than against other subtypes, subgroup analysis was performed by differential propensity to progress to colorectal cancer. Consistent with the prior evidence, 9, 11, 16, 29, 35 the linear association was stronger with high7risk adenomas (RR=0.89, 95% CI=0.8570.94, I
2 =17%, P heterogeneity =0.30, 6 prospective studies 11, 16, 27, 29, 34, 35 with 2,685 cases, range=33371,822 mg/day) than with small adenomas (RR=0.97, 95% CI=0.9471.01, I
2 =0%, P heterogeneity =0.91, 3 prospective studies 11, 16, 29 with 3,540 cases, range=33371,822 mg/day) ( Figure 2B ). Between7subgroup heterogeneity by high7risk vs. small adenomas was statistically significant (P heterogeneity =0.02). When the non7linear dose7response curve was plotted among high7risk adenomas (P non7 linearity <0.01) ( Figure 3B ), the overall slope was much steeper compared with that for total adenomas. Approximately, compared to 550 mg/day of total calcium intake, the summary RR was 0.77 (95% CI=0.7470.81) at 1000 mg/day and further reduced to 0.69 (95% CI=0.6670.73) at 1450 mg/day.
Out of the eight prospective studies 11, 14, 16, 29, 31, 34736 included in the meta7analysis on total calcium intake, three studies 14, 35, 36 reported sufficient information for dose7response meta7 analysis of supplemental calcium intake and adenoma risk. All of the three studies were from the U.S. where supplement usage is relatively high. They included a total of 4,548 cases with category7specific midpoints of supplemental calcium intake ranging from 0 to 1,366 mg/day (Supplementary Table 2 ). In the linear dose7response meta7analysis, each 300 mg/day increase in supplemental calcium intake was associated with an approximately 4% decreased risk of adenomas (RR=0.96, 95% CI=0.9370.99), with no evidence of heterogeneity (I 2 =0%, P heterogeneity =0.53) ( Figure 2C ). The small number of studies included precluded a meaningful influence analysis. Albeit low7powered due to the small number of studies included, Egger's test provided no evidence of small study effects, such as publication bias (P=0.44). The funnel plot also displayed a symmetrical shape. Non7linear dose7response meta7analysis was not conducted, as two out of the three studies had only three categories of calcium intake and thus were not eligible for the restricted cubic spline approach.
For the linear dose7response meta7analysis of total calcium intake and adenomas based on the eight prospective studies, 11, 14, 16, 29, 31, 34736 subgroup analyses were performed to explore sources of the observed moderate heterogeneity (Supplementary Table 3 ). A statistically significant inverse association persisted in most of the subgroups, suggesting robustness of the inverse association. There was evidence of between7subgroup heterogeneity by number of cases (P heterogeneity =0.03), with a stronger inverse association observed in the subgroup of studies with ≤1000 cases of adenomas. This is consistent with the observed evidence of small study effects, but an inverse association was still statistically significant in the subgroup of studies with >1000 cases of adenomas. The magnitude of an inverse association was similar regardless of adjustment for confounding by vitamin D status (determined by intake or sun exposure).
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In our dose7response meta7analyses of prospective observational studies, each 300 mg/day increase in total calcium intake was associated with an approximately 5% decreased risk of adenoma occurrence/recurrence within the 33372,229 mg/day range of total calcium intake. While a non7linear dose7response relationship was indicated with adenoma risk decreasing less steeply at higher levels of calcium intake, the degree of curvature was mild and thus, overall, a linear association reasonably approximated the shape of the relationship. The linearity was further supported by the subgroup analyses that showed equivalent results between two subgroups classified by mean/median baseline calcium intakes of study populations. Of note, a stronger association was observed for high7risk adenomas having a high propensity to progress to colorectal cancer, with an 11% reduction in adenoma risk for each 300 mg/day increase in calcium intake. This magnitude of risk reduction is consistent with the results of our previous linear dose7response meta7analysis that found a 8% decreased risk of colorectal cancer associated with each 300 mg/day increase in calcium intake. 38 The strength of the linear association might have been overestimated due to small study effects, but several lines of evidence suggest robustness of the quantitative finding. First, in the dose7response meta7analysis of supplemental calcium intake in which no evidence of small study effects was found, results were virtually the same (RR=0.96, 95% CI=0.9370.99). Second, in the meta7analysis 6 of RCTs that compared calcium supplementations of 120072000 mg/day (weighted average: 1400 mg/day) with placebo, its pooled estimate of 20% reduction in adenoma risk is consistent with that estimated from our linear dose7response meta7analysis of prospective observational studies. Given 475% reduction per 300 mg/day increase in calcium intake, 19723% reduction in adenoma risk is predicted by 1400 mg/day difference in calcium intake. Considering that heterogeneity was low in each meta7analysis of prospective observational studies on supplemental calcium and of RCTs on calcium supplements, such consistency in estimates after accounting for dose of calcium intake serves as strong evidence for robustness of our quantification of the linear dose7response relationship.
The detailed investigations of the association over a wide range of calcium intake by adenoma subtypes, particularly among high7risk adenomas, distinguish our meta7analysis from the meta7analysis of RCTs. 6 As adenomas are an etiologically heterogeneous disease with differential potential to progress colorectal cancer 2, 9 , a certain subtype could be more responsive to the chemopreventive effect of calcium. In the meta7analysis of RCTs that included a total of 407 adenomas, the power to perform subgroup analyses by adenoma subtypes was limited. For instance, in their analysis confined to large adenomas (> 0.9 cm), the confidence interval was wide (RR=0.78, 95% CI=0.5071.22). 6 In contrast, our dose7response meta7analysis on high risk adenomas included 2,685 adenomas and showed a statistically significant association, which was more pronounced than the association with small tubular adenomas. Furthermore, as the RCTs exclusively investigated recurrent adenomas, only the role of calcium intake after the diagnosis of an adenoma was able to be examined. Although the pathophysiology of occurrent and recurrent adenomas is likely to overlap, there are some differences, for example, in bowel location propensity. 39 In addition occurrent adenomas may better capture the effect of earlier dietary intake. Our meta7analysis performed a subgroup analysis to examine occurrent adenomas separately and observed a potential benefit that earlier calcium intake may confer.
Findings from our meta7analysis may inform the role of calcium in the colorectal carcinogenesis. In light of the well7established natural history of colorectal carcinogenesis by which the progression from the normal epithelium, to hyperproliferative epithelium, to aberrant cryptic foci, to small adenomas, to large adenomas, and finally to adenocarcinomas occurs over a International Journal of Cancer long duration, up to 30 to 40 years 2 , the presence of an inverse association between calcium and adenoma risk suggests that calcium may act on an early stage of the pathway. The protective role of calcium in the prevention of adenomas is also supported by several biological mechanisms. First, calcium in the colorectal lumen binds to and precipitates with secondary bile acids or ionized fatty acids, protecting the mucosa from their carcinogenic effects 40, 41 . Second, calcium has been suggested to reduce cell proliferation and promote cell differentiation and apoptosis, as a rise in extracellular calcium leads to an increase in cytosol calcium concentration of colonic epithelia cells, which in turn modulates signaling pathways related to such cell cycles 42745 . Third, given that mutations in the APC/β7catenin pathway are a common early hallmark in the colorectal carcinogenesis and that calcium was shown to induce favorable changes in the APC/β7catenin pathway 46 , calcium may prevent the initiation of the neoplastic pathogenesis.
Our meta7analysis has several limitations. First, the small number of prospective studies included precludes a definitive conclusion related to the shape of relationship and subgroup analyses. The non7linearity is strongly driven by data points in extreme values of the exposure, but we had sparse data in the high extreme of calcium intake, as shown by inner ticks on the x axis in Figure 3 . Similarly, our subgroup analyses were low7powered to identify a statistically significant source of between7subgroup heterogeneity. Second, as studies on dietary intake are prone to substantial measurement error, our meta7analyses were also affected by measurement error within each study included. Additional measurement error was introduced due to assumptions inevitable in conducting dose7response meta7analyses, such as assigning midpoint of category7specific calcium intake to the corresponding RR and equating the width of open7 ended extreme categories with that of the adjacent interval. While the direction of bias cannot be predicted, measurement error is generally anticipated to attenuate the true effect 47 , particularly since the dietary information was collected before participants' knowledge of case status. Despite diverse sources of measurement error, bias due to small study effects discussed above and bias due to measurement error are anticipated to direct opposite, offsetting each other to some degrees. Thus, our quantification of 5% reduced risk in adenoma risk for each 300 mg/day increase in calcium intake maybe a reasonable approximation.
Another limitation relates to the inclusion of prevalent cases, particularly in the occurrence studies. As most participants did not systematically undergo baseline endoscopy, some of them might have been harboring asymptomatic adenomas. Thus, the cases detected were likely to be a mixture of incident and prevalent adenomas. Inclusion of prevalent cases elicits several concerns. The first is survival bias, that is, less fatal disease subtypes are over7 represented because individuals with prevalent disease have to survive up to study baseline in order to be included. However, as adenomas are benign by themselves, existing adenomas were unlikely to have affected survival up to the study baseline, ameliorating the concern. Second, because the precise timing of the appearance of the adenoma is not known, the time relation between calcium intake and adenoma appearance is unclear. However, considering that people's diet tend to track over time, it might be acceptable to assume that calcium intake measured at study baseline were likely to reflect distant past diet prior to adenoma initiation. Furthermore, as the majority of adenomas are asymptomatic, existing adenomas would not have induced people to change their calcium intake, which diminishes the likelihood of reverse causation.
Our meta7analysis has several strengths as well. To the best of our knowledge, this is the first meta7analysis that identified and quantified the dose7response relationship between calcium intake and adenoma risk over the wide range of calcium intake. By showing consistency between meta7analysis of cohort studies and that of RCTs in terms of magnitude after adjusted International Journal of Cancer for dose, direction, and statistical significance of the association, our study provides strong evidence supporting a protective role of calcium in the prevention of adenomas. As our primary dose7response meta7analysis included only prospective studies, recall bias is unlikely to have biased the results. Indeed, the stronger linear association observed among retrospective studies might have been driven by recall bias. While case7control studies that assessed diet intake before endoscopy were parts of our primary dataset of the eight prospective studies, as both cases and controls were sampled from the well7defined primary source population of subjects who underwent an endoscopy, there is less potential for selection bias. Although confounding cannot be entirely ruled out in observational studies, the observation of the association for total and supplemental calcium intake after adjustment for multiple factors and in diverse populations (e.g. North America, Europe, Asia) argues against a confounding factor. Arguably, vitamin D might be the most likely confounder, but the results were similar across subgroups defined by adjustment for confounding by vitamin D status, for supplemental calcium intake, and in a European/Asian studies where milk is not systematically fortified with vitamin D.
In conclusion, within the range of 33372,229 mg/day total calcium intake, the risk of adenomas continued to decrease with an increasing calcium intake. Given the dose7response relationship and evidence from RCTs, calcium may be an effective chemopreventive agent against adenomas, particularly high7risk adenomas. Despite the anticipated efficacy and affordability of calcium supplements, several questions remain to be answered before clinical recommendations are made widely. Given a broadly linear association of calcium intake with adenoma risk, especially advanced adenomas, and possible harm of high7dose calcium supplements on cardiovascular disease, 7, 8 RCTs testing the effect of long7term use of low7dose calcium supplements on advanced adenoma or colorectal cancer, with additional assessment of the risk7benefit balance in terms of colorectal cancer, cardiovascular disease, and osteoporosis are warranted. 
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